Methods for diagnosis, differentiation and monitoring using urine proteins as markers in IgA nephropathy

A method of diagnosis of IgA nephropathy in a human subject, comprising:

• (a) a step of detecting a combination of alpha-1B-glycoprotein (A1BG), orosomucoid 1 (ORMI), and Ig lambda-2 chain C regions (IGLC2) as protein markers in a urine sample from said human subject, wherein the markers are detected as peptide fragments using mass spectrometry;
• (b) a step of quantitative or semi-quantitative comparison of the markers detected in step (a) with the markers detected in a urine sample from a healthy human individual;
• and
• (c) a step of correlating results obtained in step (b) with the presence of IgA nephropathy in the human subject if the levels of all markers in the examined sample from the human subject identified in step (a) are higher than the levels of the same markers present the sample from the healthy human individual.